

FORM PTO-1390
(REV. 9-2001)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

0112.00

U.S. APPLICATION NO. (If known, see 37 CFR 1.5

10/030392

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/GB00/02606 /

07 July 2000 (7.07.00) /

07 July 1999 (7.07.99)

TITLE OF INVENTION

METHOD OF PARTICLE FORMATION

APPLICANT(S) FOR DO/EO/US HANNA, Mazen, et al. /

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:

Courtesy copy of published PCT application

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/030392		INTERNATIONAL APPLICATION NO. PCT/GB00/02606		ATTORNEY'S DOCKET NUMBER 0112.00	
---	--	--	--	--	--

<p>21. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1040.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00</p> <p style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</p> <p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:20%;">CLAIMS</th> <th style="width:20%;">NUMBER FILED</th> <th style="width:20%;">NUMBER EXTRA</th> <th style="width:20%;">RATE</th> <th style="width:20%;"></th> </tr> <tr> <td>Total claims</td> <td>35 - 20 =</td> <td>15</td> <td>x \$18.00</td> <td>\$ 270.00</td> </tr> <tr> <td>Independent claims</td> <td>1 - 3 =</td> <td>0</td> <td>x \$84.00</td> <td>\$ 0.00</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ \$280.00 \$ 0.00</td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$ 1,160.00</td> </tr> <tr> <td colspan="4"> <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. </td> <td>+ \$ 0.00</td> </tr> <tr> <td colspan="4" style="text-align: right;">SUBTOTAL =</td> <td>\$ 1,160.00</td> </tr> <tr> <td colspan="4"> Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). </td> <td>\$ 0.00</td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL NATIONAL FEE =</td> <td>\$ 1,160.00</td> </tr> <tr> <td colspan="4"> Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + </td> <td>\$ 0.00</td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL FEES ENCLOSED =</td> <td>\$ 1,160.00</td> </tr> <tr> <td colspan="4"></td> <td>Amount to be refunded: \$</td> </tr> <tr> <td colspan="4"></td> <td>charged: \$</td> </tr> </table>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		Total claims	35 - 20 =	15	x \$18.00	\$ 270.00	Independent claims	1 - 3 =	0	x \$84.00	\$ 0.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$280.00 \$ 0.00	TOTAL OF ABOVE CALCULATIONS =				\$ 1,160.00	<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				+ \$ 0.00	SUBTOTAL =				\$ 1,160.00	Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ 0.00	TOTAL NATIONAL FEE =				\$ 1,160.00	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 0.00	TOTAL FEES ENCLOSED =				\$ 1,160.00					Amount to be refunded: \$					charged: \$	<p style="text-align: center;">CALCULATIONS PTO USE ONLY</p>
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																																																															
Total claims	35 - 20 =	15	x \$18.00	\$ 270.00																																																														
Independent claims	1 - 3 =	0	x \$84.00	\$ 0.00																																																														
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$280.00 \$ 0.00																																																														
TOTAL OF ABOVE CALCULATIONS =				\$ 1,160.00																																																														
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				+ \$ 0.00																																																														
SUBTOTAL =				\$ 1,160.00																																																														
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ 0.00																																																														
TOTAL NATIONAL FEE =				\$ 1,160.00																																																														
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 0.00																																																														
TOTAL FEES ENCLOSED =				\$ 1,160.00																																																														
				Amount to be refunded: \$																																																														
				charged: \$																																																														

a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 500348 in the amount of \$ 1,160.00 to cover the above fees. A duplicate copy of this sheet is enclosed.


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 500348. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Michael J. Rafa
 Inhale Therapeutic systems, Inc.
 150 Industrial Road
 San Carlos, CA 94070
 U.S.A.


 SIGNATURE
 Michael J. Rafa
 NAME
38,740
 REGISTRATION NUMBER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hanna et al.
Appl. No. : Unassigned
Filed : Herewith
For : METHOD OF PARTICLE
FORMATION

) I hereby certify that this correspondence and all
) marked attachments are being deposited with
) the United States Postal Service as Express Mail
) certificate no. EU098717597US: Assistant
) Commissioner for Patents, Washington D.C.
) 20231 on

January 7, 2002

(Date)

Kathy Honnert
Kathy Honnert

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Entry and consideration of the present Preliminary Amendment are requested prior to examination of the above-identified application on its merits.

IN THE SPECIFICATION:

On page 1 before "Field of Invention" please insert after the following new paragraph:

This application is corresponds to the U.S. national phase filing under 35 U.S.C. §371 of PCT application No. PCT/GB00/02606, filed July 7, 1999, which claims priority to UK Patent Application No. 9915975, filed July 8, 1999.

IN THE CLAIMS

Please amend the claims as follow:

- 1 A method for forming particles of a target substance, the method comprising (a) co-introducing into a particle formation vessel, the temperature and pressure in which are controlled, an anti-solvent fluid which is either a supercritical or a near-critical fluid; a solution or suspension of the target substance in a first vehicle and a second vehicle which is soluble or substantially soluble in the anti-solvent fluid; and (b) using the anti-solvent fluid to disperse the solution or suspension of the target substance and the second vehicle, and to extract the vehicles, substantially simultaneously and substantially immediately on introduction of the fluids into the particle formation vessel, wherein the second vehicle is immiscible with the first vehicle, and wherein contact between the solution or suspension of the target substance and the second vehicle occurs a sufficiently short period of time before their dispersion by the anti-solvent fluid, and with sufficient physical mixing, as to allow only insignificant, if any, phase separation to occur between the two vehicles between their contact with one another and their dispersion.
- 2 A method according to claim 1, provided that the second vehicle is not a supercritical fluid.
- 3 A method according to claim 1, wherein contact between the solution or suspension of the target substance and the second vehicle occurs within a fluid inlet [means] used to introduce the fluids into the particle formation vessel, or at or immediately before the point of entry of the vehicles into the inlet.
- 4 A method according to claim 3, wherein the contact occurs within the fluid inlet.
- 5 A method according to claim 3 wherein the second vehicle is introduced into the inlet separately from the solution or suspension of the target substance and the anti-solvent fluid, its direction of flow into the particle formation vessel being

concurrent, and coaxial or substantially coaxial, with that of the target solution/suspension.

- 6 A method according to claim 3, wherein the contact between the solution or suspension of the target substance and the second vehicle occurs either substantially simultaneously with, or immediately before, dispersion of the two vehicles by the anti-solvent fluid.
- 7 A method according to claim 6, wherein the contact occurs within about 0.001-10 seconds of the dispersion of the solution or suspension of the target substance and the second vehicle by the anti-solvent fluid.
- 8 A method according to claim 7, wherein the contact occurs within about 0.01-5 seconds of the dispersion.
- 9 A method according to claim 1, wherein the first and second vehicles are immiscible in all or substantially all proportions.
- 10 A method according to claim 9, wherein the two vehicles are immiscible at first:second vehicle molar ratios lower than 20:80.
- 11 A method according to claim 1, wherein the first vehicle is water and the second vehicle is a C₄ or higher alcohol.
- 12 A method according to claim 1, wherein the first vehicle is methanol and the second vehicle is a C₅ or higher alkane.
- 13 A method according to claim 1, wherein the first vehicle is ethylene glycol and the second vehicle is a haloalkane.
- 14 A method according to claim 1, wherein the first and second vehicles are selected from the group consisting of water and 1-butanol; water and ethyl acetate; methanol and n-pentane; methanol and n-octane; methanol and hexane; methanol and cyclohexane; DMF (dimethyl formamide) and a higher alkane; DMSO (dimethyl sulphoxide) and a higher alkane; ethyl ether and DMSO; ethylene

glycol and dichloromethane; ethylene glycol and 1,2-dichloroethane; glycerol and 3-pentanone; glycerol and ethyl acetate; 2-methoxyethanol and tetradecane; ethylformamide and hexane; 1-amino-2-propanol and isopropyl ether; 2-aminoethanol and dichloromethane; 2-aminoethanol and ethyl ether; 1,4-butanediol and butyl acetate; and water and dichloromethane.

- 15 A method according to claim 1, wherein the relative amounts of the first and second vehicles used are such that, under the operating conditions used, the solution or suspension of the target substance and the second vehicle form a single phase mixture at the time of their contact with the anti-solvent fluid.
- 16 A method according to claim 1, wherein there is an excess of the second vehicle over the first, at their point of contact with the anti-solvent fluid.
- 17 A method according to claim 16, wherein the molar ratio of the first to the second vehicle is less than 1:6.
- 18 A method according to claim 1, wherein the target substance is for use in or as a pharmaceutical or pharmaceutical excipient.
- 19 A method according to claim 1, wherein the target substance is a hydrophilic material.
- 20 A method according to claim 19, wherein the target substance is a sugar, protein or enzyme.
- 21 A method according claim 1, wherein two or more target substances are co-precipitated from the first and/or the second vehicle.
- 22 A method according to claim 1, wherein the anti-solvent fluid is a supercritical fluid.
- 23 A method according to claim 1, wherein each of the two vehicles comprises a single fluid material.

- 24 A method according to claim 1, wherein the second vehicle is an anti-solvent for the target substance, and contains a crystallisation seed of a material which is insoluble in the second vehicle, to induce nucleation of the target substance when the second vehicle comes into contact with the solution or suspension of the target substance.
- 25 A method according to claim 24, wherein the crystallisation seed is a pharmaceutically acceptable carrier and the target substance is for use in or as a pharmaceutical.
- 26 A method according to claim 24, wherein the crystallisation seed comprises a pharmaceutically active material and the target substance comprises a material to be coated onto the pharmaceutically active material.
- 27 A method according to claim 1, wherein the flow rate of the anti-solvent fluid is higher than those of the other fluids.
- 28 A method according to claim 27, wherein the ratio of the solution or suspension of the target substance flow rate to the anti-solvent flow rate, both measured at or immediately prior to the two fluids coming into contact with one another, is between 0.01 and 0.2.
- 29 A method according to claim 1, wherein at the point of extraction of the two vehicles, into the anti-solvent fluid, they together constitute between 1 and 20 mole % of the fluid mixture then formed.
- 30 A method according to claim 1, wherein the fluids are co-introduced into the particle formation vessel in a manner such that:
- (a) the anti-solvent fluid and the target solution/suspension both enter the vessel at the same or substantially the same point, which is the same or substantially the same as the point at which they meet; and
 - (b) the fluid inlet used to co-introduce the fluids is arranged so that the mechanical energy of the anti-solvent flow can facilitate intimate

mixing of the fluids and also disperse them, and so that the anti-solvent can simultaneously extract the vehicles, at the point where the fluids meet.

- 31 A method according to claim 30, wherein the anti-solvent fluid and the solution or suspension of the target substance are co-introduced into the particle formation vessel with concurrent, and coaxial or substantially coaxial, directions of flow.
- 32 A method according to claim 30, wherein the fluid inlet comprises a nozzle having an outlet end communicating with the interior of the particle formation vessel, and two or more coaxial passages which terminate adjacent or substantially adjacent one another at the outlet end.
- 33 A method according to claim 32, wherein the nozzle has three coaxial passages, an inner, an intermediate and an outer.
- 34 A method according to claim 32, wherein the outlet of an inner nozzle passage is located slightly upstream, in use, of that of a surrounding passage, to allow a degree of internal mixing between fluids introduced through the two passages.
- 35 A method according to claim 1, which additionally involves controlling one or more of (i) the flow rates of the anti-solvent fluid and/or the solution or suspension of the target substance and/or the second vehicle, (ii) the relative amounts of the two vehicles, (iii) the concentration of the target substance in the first vehicle, and (iv) the temperature and pressure inside the particle formation vessel, so as to influence the physicochemical characteristics of the particles formed.

10030392 10/030392

JC13 Rec'd PCT/PTO 07 JAN 2002

CONCLUSION


Attached hereto is a marked-up version of the changes made to the title and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Applicants believe that all the pending claims are presently in condition for allowance. However, the Examiner is invited to telephone the undersigned attorney at the number below if it is believed that this will expedite prosecution of the present application.

Respectfully submitted,

Dated: Jan 07 02

By:



Michael J. Rafa.

Registration No. 38,740

Attorney of Record

(650) 631-5053

“Version with markings to show changes made.”

In the specification:

The paragraph at page 1 before “Field of Invention is new.

In the claims:

- 36 A method for forming particles of a target substance, the method comprising (a) co-introducing into a particle formation vessel, the temperature and pressure in which are controlled, an anti-solvent fluid which is either a supercritical or a near-critical fluid; a solution or suspension of the target substance in a first vehicle [(the “target solution/suspension”)]; and a second vehicle which is soluble or substantially soluble in the anti-solvent fluid; and (b) using the anti-solvent fluid to disperse the solution or suspension of the target [solution/suspension] substance and the second vehicle, and to extract the vehicles, substantially simultaneously and substantially immediately on introduction of the fluids into the particle formation vessel, wherein the second vehicle is immiscible with the first vehicle, and wherein contact between the solution or suspension of the target [solution/suspension] substance and the second vehicle occurs a sufficiently short period of time before their dispersion by the anti-solvent fluid, and with sufficient physical mixing, as to allow only insignificant, if any, phase separation to occur between the two vehicles between their contact with one another and their dispersion.
- 37 A method according to claim 1, provided that the second vehicle is not a supercritical fluid.
- 38 A method according to claim 1 [or claim 2], wherein contact between the solution or suspension of the target [solution/suspension] substance and the second vehicle occurs within a fluid inlet [means] used to introduce the fluids into the particle formation vessel, or at or immediately before the point of entry of the vehicles into the inlet [means].

- 39 A method according to claim 3, wherein the contact occurs within the fluid inlet [means].
- 40 A method according to claim 3 [or claim 4], wherein the second vehicle is introduced into the inlet [means] separately from the solution or suspension of the target [solution/suspension] substance and the anti-solvent fluid, its direction of flow into the particle formation vessel being concurrent, and coaxial or substantially coaxial, with that of the target solution/suspension.
- 41 A method according to [any one of claims 3 to 5] claim 3, wherein the contact between the solution or suspension of the target [solution/suspension] substance and the second vehicle occurs either substantially simultaneously with, or immediately before, dispersion of the two vehicles by the anti-solvent fluid.
- 42 A method according to claim 6, wherein the contact occurs within about 0.001-10 seconds of the dispersion of the solution or suspension of the target [solution/suspension] substance and the second vehicle by the anti-solvent fluid.
- 43 A method according to claim 7, wherein the contact occurs within about 0.01-5 seconds of the dispersion.
- 44 A method according to [any one of the preceding claims] claim 1, wherein the first and second vehicles are immiscible in all or substantially all proportions.
- 45 A method according to claim 9, wherein the two vehicles are immiscible at first:second vehicle molar ratios lower than 20:80.
- 46 A method according to [any one of the preceding claims] claim 1, wherein the first vehicle is water and the second vehicle is a C₄ or higher alcohol.
- 47 A method according to [any one of claims 1 to 10] claim 1, wherein the first vehicle is methanol and the second vehicle is a C₅ or higher alkane.
- 48 A method according to [any one of claims 1 to 10] claim 1, wherein the first vehicle is ethylene glycol and the second vehicle is a haloalkane.

- 49 A method according to [any one of the preceding claims] claim 1, wherein the first and second vehicles are selected from the group consisting of water and 1-butanol; water and ethyl acetate; methanol and n-pentane; methanol and n-octane; methanol and hexane; methanol and cyclohexane; DMF (dimethyl formamide) and a higher alkane; DMSO (dimethyl sulphoxide) and a higher alkane; ethyl ether and DMSO; ethylene glycol and dichloromethane; ethylene glycol and 1,2-dichloroethane; glycerol and 3-pentanone; glycerol and ethyl acetate; 2-methoxyethanol and tetradecane; ethylformamide and hexane; 1-amino-2-propanol and isopropyl ether; 2-aminoethanol and dichloromethane; 2-aminoethanol and ethyl ether; 1,4-butanediol and butyl acetate; and water and dichloromethane.
- 50 A method according to [any one of the preceding claims] claim 1, wherein the relative amounts of the first and second vehicles used are such that, under the operating conditions used, the solution or suspension of the target [solution/suspension] substance and the second vehicle form a single phase mixture at the time of their contact with the anti-solvent fluid.
- 51 A method according to [any one of the preceding claims] claim 1, wherein there is an excess of the second vehicle over the first, at their point of contact with the anti-solvent fluid.
- 52 A method according to claim 16, wherein the molar ratio of the first to the second vehicle is less than 1:6.
- 53 A method according to [any one of the preceding claims] claim 1, wherein the target substance is for use in or as a pharmaceutical or pharmaceutical excipient.
- 54 A method according to [any one of the preceding claims] claim 1, wherein the target substance is a hydrophilic material.
- 55 A method according to claim 19, wherein the target substance is a sugar, protein or enzyme.

- 64 A method according to [any one of the preceding claims] claim 1, wherein at the point of extraction of the two vehicles, into the anti-solvent fluid, they together constitute between 1 and 20 mole % of the fluid mixture then formed.
- 65 A method according to [any one of the preceding claims] claim 1, wherein the fluids are co-introduced into the particle formation vessel in a manner such that:
 - (a) the anti-solvent fluid and the target solution/suspension both enter the vessel at the same or substantially the same point, which is the same or substantially the same as the point at which they meet; and
 - (b) the fluid inlet used to co-introduce the fluids is arranged so that the mechanical energy of the anti-solvent flow can facilitate intimate mixing of the fluids and also disperse them, and so that the anti-solvent can simultaneously extract the vehicles, at the point where the fluids meet.
- 66 A method according to claim 30, wherein the anti-solvent fluid and the solution or suspension of the target [solution/suspension] substance are co-introduced into the particle formation vessel with concurrent, and coaxial or substantially coaxial, directions of flow.
- 67 A method according to claim 30 [or claim 31], wherein the fluid inlet comprises a nozzle having an outlet end communicating with the interior of the particle formation vessel, and two or more coaxial passages which terminate adjacent or substantially adjacent one another at the outlet end.
- 68 A method according to claim 32, wherein the nozzle has three coaxial passages, an inner, an intermediate and an outer.
- 69 A method according to claim 32 [or claim 33], wherein the outlet of an inner nozzle passage is located slightly upstream, in use, of that of a surrounding passage, to allow a degree of internal mixing between fluids introduced through the two passages.

- 70 A method according to [any one of the preceding claims] claim 1, which additionally involves controlling one or more of (i) the flow rates of the anti-solvent fluid and/or the solution or suspension of the target [solution/suspension] substance and/or the second vehicle, (ii) the relative amounts of the two vehicles, (iii) the concentration of the target substance in the first vehicle, and (iv) the temperature and pressure inside the particle formation vessel, so as to influence the physicochemical characteristics of the particles formed.

Please delete claim 36

10/p.r.s

WO 01/03821

PCT/GB00/02606

METHOD OF PARTICLE FORMATION

Field of the invention

This invention relates to a method for the formation of particles of a target
5 substance, using a supercritical or near-critical fluid as an anti-solvent.

Background to the invention

Methods are already known in which a supercritical fluid is used as an anti-
solvent to precipitate particles of a substance of interest from solution or suspension.
10 One such method is known as "SEDS"TM ("Solution Enhanced Dispersion by
Supercritical fluids") and is disclosed in WO-95/01221. In SEDSTM, a target
substance is dissolved or suspended in an appropriate vehicle, and the solution or
suspension then co-introduced into a particle formation vessel with a supercritical anti-
solvent fluid in which the vehicle is soluble. The co-introduction is effected in a
15 particular way, to ensure that:

- both the solution/suspension and the supercritical fluid enter the vessel at
substantially the same point, which is also the same or substantially the same as the
point where they meet; and
- in the region where the fluids meet and enter the vessel, the mechanical
20 energy of the supercritical fluid serves to disperse the solution/suspension (ie, to break
it up into individual fluid elements) *at the same time as* the supercritical fluid extracts
the vehicle so as to cause particle formation.

Thus, in SEDSTM, the supercritical fluid serves not only as an anti-solvent but
also as a mechanical dispersing agent. The simultaneity of fluid contact, dispersion and
25 particle formation provides a high degree of control over the physicochemical
properties of the particulate product.

One particular embodiment of SEDSTM is described in WO-96/00610. The
target substance is dissolved or suspended in a first vehicle, and the
solution/suspension is then contacted, either at or immediately prior to its contact with
30 the co-introduced anti-solvent, with a second vehicle. The second vehicle must be

WO 01/03821

PCT/GB00/02606

soluble in the anti-solvent but the first need not be, since both vehicles are extracted together into the anti-solvent. This embodiment widens the applicability of the basic SEDS™ technique to further target substances and vehicles: a first vehicle may be used which would not otherwise be extractable into the chosen anti-solvent but which is compatible with the target substance, and a second vehicle may be used which, although extractable into the anti-solvent, is less compatible with the target substance.

The method disclosed in WO-96/00610 requires the first and second vehicles to be miscible with one another, preferably in all proportions. This naturally constrains the choice of vehicle pairs available for use with any given target substance and anti-solvent.

The present invention aims to provide an alternative method for particle formation, embodiments of which can be used to widen the choice of useable target substance/vehicle/anti-solvent combinations.

15 Statements of the invention

According to the present invention there is provided a method for forming particles of a target substance, the method comprising (a) co-introducing into a particle formation vessel, the temperature and pressure in which are controlled, an anti-solvent fluid which is either a supercritical or a near-critical fluid; a solution or suspension of the target substance in a first vehicle (the "target solution/suspension"); and a second vehicle which is soluble or substantially soluble in the anti-solvent fluid; and (b) using the anti-solvent fluid to disperse the target solution/suspension and the second vehicle, and to extract the vehicles, substantially simultaneously and substantially immediately on introduction of the fluids into the particle formation vessel, wherein the second vehicle is immiscible with the first vehicle, and wherein contact between the target solution/suspension and the second vehicle occurs a sufficiently short period of time before their dispersion by the anti-solvent fluid, and with sufficient physical mixing, as to allow only insignificant, if any, phase separation to occur between the two vehicles between their contact with one another and their dispersion.

Ideally, contact between the target solution/suspension and the second vehicle

WO 01/03821

PCT/GB00/02606

occurs either substantially simultaneously with, or immediately before, dispersion of the two vehicles by the anti-solvent fluid.

The method of the present invention is therefore a modified version of that disclosed in WO-96/00610. However, whereas WO-96/00610 emphasises throughout
5 that the first and second vehicles should be *miscible* with one another, in order that both may be extracted into the anti-solvent together, we have now surprisingly found that *immiscible* vehicle pairs may be used in an analogous fashion, and can still be extracted together into a suitable supercritical or near-critical anti-solvent. Other prior art particle formation techniques which make use of supercritical or near-critical fluid
10 anti-solvents also fail to recognise that immiscible vehicles may be paired together.

The invention can thus widen the choice of vehicle pairs available for any given target substance(s) and anti-solvent in a SEDS™ process. In addition, it can help to reduce or eliminate so-called solvent/anti-solvent effects that can arise when using two vehicles together. A given target substance may, for instance, be highly soluble in the
15 first vehicle but only sparingly soluble in the second. The immiscibility of the two vehicles, in the method of the present invention, means that the second cannot to any significant degree act as an anti-solvent for the target substance, thus avoiding nucleation of the target prior to contact with the anti-solvent fluid (which might otherwise take place upstream of the particle formation vessel, causing apparatus
20 blockages).

Contact between the target solution/suspension and the second vehicle must not occur too long before they contact the anti-solvent fluid, otherwise the two immiscible vehicles can separate into distinct phases leading to inhomogeneous fluid flows and loss of control over the particle formation process. Any such phase
25 separation should be on a sufficiently small scale, and occur for a sufficiently short period of time, that the anti-solvent still in effect (ie, under the timescales used) disperses a uniform mixture of the target solution/suspension and the second vehicle. Thus, the contact preferably occurs either *within* the fluid inlet means (such as a nozzle) used to introduce the fluids into the particle formation vessel, or at or
30 immediately before the point of entry of the vehicles into the inlet means. More

WO 01/03821

PCT/GB00/02606

between the anti-solvent fluid contacting the vehicles, and the fluids entering the particle formation vessel) as preferably to eliminate, or substantially eliminate, the risk of particle formation occurring upstream of the particle formation vessel. The timing of the contact between the target solution/suspension and the second vehicle, relative to that of their dispersion by the anti-solvent fluid, will depend on the nature of the fluids (in particular the degree of immiscibility of the two vehicles), the target substance and the desired end product, as well as on the size and geometry of the particle formation vessel and the fluid inlet means and on the fluid flow rates. The contact may occur within about 0.001-10 seconds, more preferably within about 0.01-5 seconds, most preferably within about 0.01-1 second, of the dispersion.

"Substantially polar" encompasses polarities of 3 or higher, preferably 4 or higher, more preferably 5 or higher (see "Burdick & Jackson Solvent Guide, 3rd Edn", Burdick & Jackson, Michigan USA, 1990). "Substantially non-polar" encompasses polarities of less than 3, preferably 2 or less, more preferably 1 or less.

All references to solubilities, miscibilities and polarities are to the relevant fluid characteristics under the operating conditions used, ie, under the chosen conditions of temperature and pressure and taking into account any modifiers present in the fluids.

As used herein, the term "supercritical fluid" means a fluid at or above its critical pressure (P_c) and critical temperature (T_c) simultaneously. In practice, the pressure of the fluid is likely to be in the range $(1.01 - 9.0)P_c$, preferably $(1.01 - 7.0)P_c$, and its temperature in the range $(1.01 - 4.0)T_c$ (measured in Kelvin). However, some fluids (eg, helium and neon) have particularly low critical pressures and temperatures, and may need to be used under operating conditions well in excess of (such as up to 200 times) those critical values.

The term "near-critical fluid" encompasses both high pressure liquids, which are fluids at or above their critical pressure but below (although preferably close to) their critical temperature, and dense vapours, which are fluids at or above their critical temperature but below (although preferably close to) their critical pressure.

By way of example, a high pressure liquid might have a pressure between about 1.01 and 9 times its P_c , and a temperature between about 0.5 and 0.99 times its T_c . A

WO 01/03821

PCT/GB00/02606

dense vapour might, correspondingly, have a pressure between about 0.5 and 0.99 times its P_c , and a temperature between about 1.01 and 4 times its T_c .

The terms "supercritical fluid" and "near-critical fluid" each encompass a mixture of fluid types, so long as the mixture is in the supercritical or near-critical state
5 respectively.

The term "vehicle" means a fluid which is able to carry a solid or solids in solution or suspension. A vehicle may be composed of one or more component fluids, eg, it may be a mixture of two or more solvents. Both first and second vehicles may be soluble (or substantially soluble) in the chosen anti-solvent fluid, although it is only
10 *essential* that the second vehicle has this characteristic. Either vehicle may contain, in solution or suspension, other materials apart from the target substance.

The terms "supercritical solution" and "near-critical solution" mean respectively a supercritical or a near-critical fluid together with one or more vehicles which it has extracted and dissolved. The solution should itself still be in the
15 supercritical or near-critical state, as the case may be, and as a single phase, at least within the particle formation vessel.

The terms "disperse" and "dispersion" refer generally to the transfer of kinetic energy from one fluid to another. They usually imply the formation of droplets, or of other analogous fluid elements, of the fluid to which the kinetic energy is transferred,
20 typically of the target solution/suspension and/or of a vehicle.

The present invention relies on the mixing of the target solution/suspension, before or substantially simultaneously with its dispersion by the anti-solvent fluid, with a second vehicle specially chosen to be soluble in, or miscible with, the anti-solvent. On contact with the anti-solvent, the first vehicle is able to dissolve into the anti-
25 solvent *with the second vehicle*, even if the first vehicle is not itself soluble in the anti-solvent. In other words, the two vehicles may effectively be extracted together by the anti-solvent to form a supercritical or near-critical solution.

In the case where the first vehicle is less than substantially soluble in the anti-solvent fluid (for instance, it has a solubility of 2 or even 1 mole % or less in the anti-
30 solvent), the present invention can make use of a "dilution" of the target

WO 01/03821

PCT/GB00/02606

solution/suspension in a relatively large amount of the second vehicle; in this case there is therefore preferably an excess of the second vehicle over the first, at their point of contact with the anti-solvent fluid.

The method of the invention can retain all the advantages of the methods described in WO-95/01221 and WO-96/00610. It can provide the opportunity for manufacturing dry particulate products with highly controlled particle size, shape and other physicochemical characteristics.

The simultaneous co-introduction of the target solution/suspension, the second vehicle and the anti-solvent fluid, into the particle formation vessel, allows a high degree of control over operating parameters such as temperature, pressure and fluid flow rates, at the exact point when the fluids come into contact with one another and hence at the point of actual particle formation. Importantly, the anti-solvent acts both to *disperse* and to *extract* the two vehicles, as well as to ensure their thorough mixing - because of this, controlling the relative flow rates of the fluids into the particle formation vessel allows accurate control over the size of the fluid elements formed on dispersion of the vehicles, and hence of the particles formed substantially simultaneously by extraction of the vehicles into the anti-solvent fluid.

The target substance may be any substance which needs to be produced in particulate form. Examples include pharmaceuticals; pharmaceutical excipients such as carriers; dyestuffs; foodstuffs; coatings; agrochemicals; products of use in the ceramics, explosives or photographic industries; etc... It may be organic or inorganic, monomeric or polymeric. It may in particular be a hydrophilic material such as a sugar, protein or enzyme.

In a preferred embodiment of the invention, the target substance is for use in or as a pharmaceutical or pharmaceutical excipient.

The target substance will typically (although not always) either be or comprise a substance which is soluble or substantially soluble only in solvents which are themselves substantially insoluble in the chosen anti-solvent fluid. It may be a substance which, though soluble in an appropriate anti-solvent-soluble vehicle, would be in some way incompatible with that vehicle. It is preferably, however, soluble or

WO 01/03821

PCT/GB00/02606

substantially soluble in the first vehicle, preferably having a solubility in it of 10^{-4} mole % or greater. It may even be soluble, at least to a degree, in both the first and the second vehicles.

The target substance may be in a single or multi-component form (eg, it could
5 comprise an intimate mixture of two materials, or one material in a matrix of another, or one material coated onto a substrate of another, or other similar mixtures). The particulate product, formed from the target substance using the method of the invention, may also be in such a multi-component form - such products may be made from solutions/suspensions containing only single component starting materials,
10 provided the solutions/suspensions are co-introduced with the anti-solvent fluid in the correct manner. The particulate product may comprise a substance formed from an *in situ* reaction (ie, immediately prior to, or on, dispersion by the anti-solvent) between two or more reactant substances each carried by an appropriate vehicle.

The method of the present invention is particularly suitable for co-precipitating
15 two or more target substances, such as for example two pharmaceuticals intended for co-administration, or a pharmaceutical together with a polymer carrier matrix (many such polymers are water soluble, and the present invention allows the use of an aqueous first vehicle even though water is insoluble in, for instance, the common anti-solvent supercritical carbon dioxide). To perform such co-precipitations, target
20 substance(s) may be carried in the second vehicle and/or the anti-solvent fluid, as well as in the first vehicle.

The anti-solvent fluid is preferably a supercritical fluid. It may for instance be carbon dioxide, nitrogen, nitrous oxide, sulphur hexafluoride, xenon, ethylene, chlorotrifluoromethane, ethane, trifluoromethane or a noble gas such as helium or
25 neon, in an appropriate condition with respect to its critical temperature and pressure. A particularly preferred anti-solvent is carbon dioxide, more preferably supercritical carbon dioxide, due to its relatively low cost, toxicity, flammability and critical temperature.

It must be capable of acting as an anti-solvent for the target substance.
30 Therefore, although it must be miscible or substantially miscible with the second

WO 01/03821

PCT/GB00/02606

vehicle so that it can extract the vehicle mixture, it must not at that point extract or dissolve the target substance as particles are formed. In other words, it must be chosen so that the target substance is for all practical purposes (in particular, under the chosen operating conditions and taking into account any fluid modifiers present)

5 insoluble or substantially insoluble in it. Preferably the target substance is less than 10^{-3} mole %, more preferably less than 10^{-5} mole %, soluble in the anti-solvent fluid.

The anti-solvent fluid may optionally contain one or more modifiers, for example water, methanol, ethanol, isopropanol or acetone. A modifier (or co-solvent) may be described as a chemical which, when added to a fluid such as a supercritical or

10 near-critical fluid, changes the intrinsic properties of that fluid in or around its critical point, in particular its ability to dissolve other materials. When used, a modifier preferably constitutes not more than 40 mole %, more preferably not more than 20 mole %, and most preferably between 1 and 10 mole %, of the anti-solvent fluid.

The choice of first and second vehicles in any particular case will depend on the

15 nature of the target substance and the anti-solvent fluid, and on other practical criteria including those governing the desired end product. Either vehicle may comprise a mixture of two or more fluids which together have the necessary characteristics (such as solubility, miscibility and polarity) vis-a-vis the target substance and the other fluids involved. Alternatively, each of the vehicles may comprise a single fluid material

20 rather than a mixture.

The choice of a suitable combination of anti-solvent fluid, modifier (where desired) and vehicles for any desired product will be well within the capabilities of a person of ordinary skill in the art.

Examples of suitable immiscible first/second vehicle pairs include water and

25 higher (ie, C_4 or greater) alcohols such as 1-butanol; water and ethyl acetate; methanol and higher (ie, C_3 or greater) alkanes (including cycloalkanes) such as n-pentane, n-octane, hexane and cyclohexane; DMF (dimethyl formamide) and higher alkanes; DMSO (dimethyl sulphoxide) and higher alkanes; ethyl ether and DMSO; ethylene glycol and haloalkanes such as dichloromethane or 1,2-dichloroethane; glycerol and 3-

30 pentanone; glycerol and ethyl acetate; 2-methoxyethanol and tetradecane;

WO 01/03821

PCT/GB00/02606

ethylformamide and hexane; 1-amino-2-propanol and isopropyl ether; 2-aminoethanol and dichloromethane; 2-aminoethanol and ethyl ether; 1,4-butanediol and butyl acetate; and water and dichloromethane. This list is clearly not exhaustive.

5 In the method of the invention, the target substance and the first vehicle may be substantially polar, and the second vehicle substantially non-polar. In contrast, a substantially non-polar substance may be dissolved in a substantially non-polar first vehicle, the second vehicle then being substantially polar. These two sets of conditions are of particular use when the second vehicle acts as an *anti-solvent* for the target substance, ie, when the target substance carried in the first vehicle is *insoluble*, or
10 substantially so, in the second vehicle.

In such a case, if the first and second vehicles are not *completely* immiscible with one another, the second vehicle can help to cause precipitation of the target substance on contact with the target solution/suspension. The second vehicle may then contain a "seed" of the target substance, or indeed of any other suitable material
15 (insoluble in the second vehicle), to induce nucleation of the target substance when the second vehicle comes into contact with the target solution/suspension. The seed may be, for example, a pharmaceutically acceptable carrier where the target substance is a pharmaceutical, or it may itself be a pharmaceutically active material, to be coated with a substance, such as a taste-masking agent, which is precipitated out of the first vehicle
20 onto the seed.

When carrying out this version of the invention, the various fluids should be introduced into the particle formation vessel in such a way that the second vehicle and the target solution/suspension contact one another before, and preferably immediately before, their contact with the anti-solvent fluid. The target solution/suspension should
25 also, generally, be highly saturated. The second vehicle, when it contacts the target solution/suspension, dramatically increases the supersaturation ratio of the resultant mixture, causing the formation of embryos or nucleation sites which can act as centres of crystallisation for the target substance. After and preferably immediately after this, the mixture (containing growing particle embryos) is dispersed by the anti-solvent
30 fluid, and simultaneously the two vehicles are rapidly extracted into the anti-solvent,

WO 01/03821

PCT/GB00/02606

leading to the formation of a dry particulate product. This allows a high level of control over the growth of the particles and hence over their ultimate physicochemical characteristics.

As mentioned previously, if the first vehicle is less than substantially soluble in the anti-solvent fluid, there is preferably an excess of the second vehicle at the point of its contact with the first. This can be achieved, for instance, by appropriate selection of flow rates for the two vehicles on their introduction into the particle formation vessel. An excess of the second vehicle over the first can also be desirable in other cases, for instance when the two vehicles are immiscible in most but not all proportions.

Generally speaking the relative amounts of first and second vehicles used will depend on the natures of all the fluids involved, the operating conditions, the nature of the target substance and the desired product characteristics. The molar ratio of the two vehicles at the point of particle formation may range, for instance, between 1:99 and 99:1. It must of course be chosen so that the two vehicles are still extractable, *together*, into the anti-solvent fluid so it will depend in particular on the solubilities of the vehicles in the anti-solvent under the chosen operating conditions. Ideally it is chosen so that, under the operating conditions used, the target solution/suspension and the second vehicle form a single phase mixture at the point of particle formation.

For an excess of the second vehicle, the molar ratio of the first to the second vehicle may be less than 1:1.5 (for instance, between 1:100 and 1:1.5), preferably less than 1:4, more preferably less than 1:6, most preferably less than 1:9 or 1:10 or 1:20.

It may also be desirable to use the minimum possible amount of the first vehicle to solvate the target substance so as to create a single phase solution.

The amounts of the vehicles used, and their relative flow rates, may also depend on whether it is intended that some of the vehicle(s) remain in the final particulate product. For instance, if the first vehicle were water, then the amount used could affect whether the target substance were precipitated in an anhydrous form, or in the form of its monohydrate, dihydrate, or whatever. Thus, the concentration of the first, or indeed the second, vehicle in the eventual mixture of vehicles may be used to

WO 01/03821

PCT/GB00/02606

control "doping" of the final particulate product with vehicle "impurities". The invention allows a high degree of control over the residual vehicle content of the product.

5 In certain cases, the amount of the first vehicle (for instance, water) used may also determine which crystalline form of the target substance is formed.

When carrying out the present invention, the conditions in the particle formation vessel must generally be such that the anti-solvent fluid, and the supercritical or near-critical solution which is formed when it extracts the two vehicles, both remain in the supercritical/near-critical form whilst in the vessel. For the supercritical/near-critical solution, this means that at least one of its constituent fluids (usually the anti-solvent fluid, which in general will be the major constituent of the mixture) should be
10 in a supercritical or near-critical state at the time of particle formation. There should at that time be a *single-phase* mixture of the two vehicles and the anti-solvent fluid, otherwise the particulate product might be distributed between two or more fluid
15 phases, in some of which it might be able to redissolve. This is why the anti-solvent fluid needs to be miscible or substantially miscible with at least the second vehicle.

Provided such conditions are applied, extraction of the vehicles is then effectively immediate when the target solution/suspension and second vehicle contact the anti-solvent. This allows the rapid formation of a pure, dry particulate product.

20 The operating temperature and pressure (ie, within the particle formation vessel) and the fluid flow rates needed to achieve this situation will depend on the natures of the fluids involved (in particular, their P_c and T_c values and their solubility and miscibility curves) but will also be affected by the characteristics desired of the particulate end product, for instance a high yield, or a certain particle size or shape or
25 purity. If for instance the objective is a high product yield, then it might be preferable (when using a supercritical fluid anti-solvent) to maintain the pressure inside the particle formation vessel substantially in excess of the anti-solvent P_c (for instance, between 4 and 9 times the P_c , say 100-300 bar for carbon dioxide) whilst the temperature is only slightly above the T_c (for instance, between 1.01 and 2 times the
30 T_c , say 40-60°C for carbon dioxide).

WO 01/03821

PCT/GB00/02606

If however the objective is smaller particles with a narrower size distribution, then (subject to the constraints imposed by the relevant P_c and T_c values) higher temperatures (eg, between about 2 and 4 times the T_c) may be preferred for the anti-solvent fluid, since they lower its viscosity and can hence improve its dispersing effect on the other fluids.

For some target substances, the product morphology can be heavily influenced by the state of the anti-solvent fluid. For example, nicotinic acid particles prepared using the method of the invention, with supercritical carbon dioxide as the anti-solvent, will precipitate as rounded particles of about 100 micron average diameter when the anti-solvent is in a liquid-like phase (ie, at a relatively high pressure and low temperature with respect to its critical point), but as well-faceted, octagonal particles with an average diameter of less than 10 micron when the anti-solvent is more gas-like (higher temperature, lower pressure).

A major advantage of the present invention is therefore its versatility, different product characteristics being achievable simply by varying the operating conditions.

The flow rate of the anti-solvent fluid relative to those of the other fluids, and its pressure and temperature, should be sufficient to allow it to accommodate the vehicles (generally, the vehicles will represent no more than around 5% v/v of the anti-solvent fluid), so that it can extract them and hence cause particle formation. The anti-solvent flow rate should therefore generally be higher than those of the other fluids - typically, the ratio of the target solution/suspension flow rate to the anti-solvent flow rate (both measured at or immediately prior to the two fluids coming into contact with one another) will be 0.001 or greater, preferably between 0.01 and 0.2, more preferably between about 0.03 and 0.1.

The flow rate of the anti-solvent fluid, relative to those of the other fluids, is particularly important because it acts to *disperse* the two vehicles. Its flow rate can therefore affect the size and size distribution of fluid elements caused by the dispersion, and hence of the particles formed by extracting the vehicles from those fluid elements; a higher flow rate is preferred so as to generate correspondingly smaller fluid elements with a narrower particle size distribution.

WO 01/03821

PCT/GB00/02606

The anti-solvent flow rate will also generally be chosen to ensure an excess of the anti-solvent over the two vehicles when the fluids come into contact, to minimise the risk of the vehicles re-dissolving and/or agglomerating the particles formed. At the point of extraction of the two vehicles they may together constitute between 1 and 80 mole %, preferably 50 mole % or less or 30 mole % or less, more preferably between 1 and 20 mole % and most preferably between 1 and 5 mole %, of the fluid mixture formed.

Because the present invention is a modified version of that disclosed in WO-96/00610, technical features of the processes described in WO-96/00610 and its precursor WO-95/01221 (and also in the later but related document WO-98/36825) can apply also to the present invention. The three earlier documents are therefore intended to be read together with the present application.

In particular, the fluids are preferably co-introduced into the particle formation vessel in the manner described in WO-95/01221, ie:

(a) the anti-solvent fluid and the target solution/suspension both enter the vessel at the same or substantially the same point, which is the same or substantially the same as the point at which they meet; and

(b) the fluid inlet used to co-introduce the fluids is arranged so that the mechanical energy (typically the shearing action) of the anti-solvent flow can facilitate intimate mixing of the fluids and also disperse them, and so that the anti-solvent can simultaneously extract the vehicles, at the point where the fluids meet.

The vessel temperature and pressure are ideally controlled so as to allow particle formation to occur at or substantially at the point where the vehicle mixture meets the anti-solvent fluid.

The fluid inlet may be of the type which allows "pre-filming" or "sheathing" of at least one of the fluids to occur, immediately prior to its dispersion by an impinging flow of another fluid introduced through the inlet means. For instance, the inlet means can be used to cause pre-filming of the target solution/suspension, and/or of the second vehicle, immediately prior to their dispersion by the anti-solvent fluid. This means that the dimensions of the inlet passages of the inlet means, and the relative positions of

WO 01/03821

PCT/GB00/02606

their outlets, must be such that a fluid entering through one passage is formed, as it reaches the outlet of that passage, into a thin film or sheath, by its contact with, say, the lip of an adjacent passage outlet. This film or sheath can then be stretched, and ultimately dispersed into separate fluid elements, when it comes into contact with an
5 oncoming stream of a fluid in another inlet passage. Clearly, the thickness of the film or sheath, and hence the sizes of the fluid elements formed on dispersion, will depend to a large extent on the relative flow rates of the fluids, and also on the inlet passage dimensions.

In one embodiment of the invention, the anti-solvent fluid and the target
10 solution/suspension, and preferably also the second vehicle, are co-introduced into the particle formation vessel with concurrent directions of flow, preferably with coaxial or substantially coaxial flows, such as using a multi-passage coaxial nozzle. Such a nozzle has an outlet end communicating with the interior of the particle formation vessel, and two or more coaxial, conveniently concentric, passages which terminate
15 adjacent or substantially adjacent one another at the outlet end, at least one of the passages serving to introduce a flow of the anti-solvent fluid into the particle formation vessel, at least one of the passages serving to introduce a flow of the target solution/suspension and preferably at least one of the passages serving to introduce a flow of the second vehicle. The three fluids may then be allowed to meet only at or
20 immediately before the outlet end of the nozzle.

Aspects of the construction and geometry of such a coaxial nozzle may be as described in WO-95/01221 or WO-96/00610. For instance, the opening at the outlet end (tip) of the nozzle will preferably have a diameter in the range of 0.005 to 5 mm, more preferably 0.05 to 2 mm, most preferably between 0.1 and 0.5 mm, for instance
25 about 0.1, 0.2, 0.3 or 0.35 mm. The angle of taper of the outlet end (with respect to the longitudinal axis of the nozzle) will depend on the desired velocity of the fluids introduced through the nozzle; a change in the angle may be used, for instance, to increase the velocity of the anti-solvent fluid and hence to increase the amount of its physical contact with the target solution/suspension and the second vehicle, leading to
30 more efficient fluid mixing. Typically, the angle of taper will be in the range 10° to

WO 01/03821

PCT/GB00/02606

60°, preferably between 10° and 50°, more preferably between 20° and 40°, and most preferably about 30°. Alternatively, the outlet need not be tapered at all.

The nozzle may be made of any appropriate material, for example stainless steel. It may have three coaxial passages, an inner, an intermediate and an outer, to
5 allow both vehicles, and the anti-solvent fluid, to be introduced separately into the particle formation vessel. However, the nozzle may have any appropriate number of coaxial passages, some of which may be used to introduce additional reagents. One or more of the passages may be used to introduce two or more fluids at the same time, and the inlets to such passages may be modified accordingly.

10 As an example of this, the target solution/suspension may be introduced through one nozzle passage, whilst the anti-solvent fluid and the second vehicle are introduced together through another. Mixing of the two vehicles then occurs simultaneously with their dispersion and extraction by the anti-solvent. This may be effected using a two-passage nozzle or, using a nozzle having three or more passages,
15 the target solution/suspension may be introduced between an inner and an outer flow of the anti-solvent/second vehicle mixture, which improves dispersion and mixing by exposing both sides of the target solution/suspension to the anti-solvent and second vehicle.

The internal diameters of the coaxial passages may be chosen as appropriate for
20 any particular case. Typically, for a three-passage nozzle, the ratio of the internal diameters of the outer and the inner passages may be in the range from 2 to 10, preferably between 2 and 5, more preferably between 3 and 4. The ratio of the internal diameters of the outer and intermediate passages may be in the range from 1.01 to 5, preferably between 1.2 and 3. For a two-passage nozzle, the ratio of the internal
25 diameters of the outer and inner passages may be in the range from 1 to 10, preferably between 2 and 6, more preferably between 2 and 4.

The outlets of two or more of the passages may be relatively staggered along the longitudinal axis of the nozzle, ie, one passage may terminate slightly upstream or downstream, in use, of another. The distance between the passage outlets should be
30 sufficient to ensure, within the nozzle, good physical contact between and efficient

mixing of the fluids introduced through the relevant passages, and so may be affected by other operating conditions such as pressure, temperature, fluid densities and viscosities and their flow rates. Typical values are between about 0.05 and 10 mm, preferably between about 0.05 and 5 mm, more preferably between about 0.5 and 3.5 mm, most preferably about 3 mm.

As an example, the outlet of an inner passage may be located slightly upstream of that of a surrounding passage, to allow a degree of internal mixing between fluids introduced through the two passages. This may be useful for instance when the target substance is insoluble in the second vehicle, the internal mixing resulting in a degree of initial particle precipitation. The target solution/suspension and the second vehicle are introduced through the inner passage and surrounding passage in question. The anti-solvent fluid may then be introduced through a passage surrounding the two already mentioned, and will contact the mixture, causing dispersion and extraction to occur, downstream of the initial point of mixing. The relative flow rates of the fluids will determine how soon after mixing the two vehicles will be dispersed by the anti-solvent; typically, as explained above, very short time intervals will be desired.

A nozzle having more than three coaxial passages may of course be used in this version of the invention. For instance, a nozzle having four or more passages may be used to introduce the target solution/suspension and the second vehicle (and preferably to cause their pre-filming), *between* an inner and an outer flow of the anti-solvent fluid. Again, the two passages carrying the target solution/suspension and the second vehicle may have staggered outlets, to allow pre-mixing to take place within the nozzle.

A fluid inlet means of the type described in WO-98/36825 (which provides two impinging flows of anti-solvent fluid) may also be used in the method of the present invention.

Control of parameters such as size, size distribution, shape and crystalline form in the particulate product will be dependent upon the operating conditions used when carrying out the method of the invention. Variables include the flow rates of the anti-solvent fluid and/or the target solution/suspension and/or the second vehicle, the

WO 01/03821

PCT/GB00/02606

relative amounts of the two vehicles, the concentration of the target substance in the first vehicle, and (as discussed above) the temperature and pressure inside the particle formation vessel. The method of the invention preferably involves controlling one or more of these variables so as to influence the physicochemical characteristics of the particles formed.

The fluid flow rates, together with the concentration of the target substance in the first vehicle, are ideally selected so as to minimise the risk of particle precipitation in, and hence blockage of, the fluid inlet or other upstream apparatus parts. For the same reason, back-flow of the anti-solvent fluid, into the supply line for the target solution/suspension or the second vehicle, is also ideally reduced or eliminated. This may be done for instance by installing a one-way valve in the target solution/suspension supply line and/or in the second vehicle supply line, upstream of and preferably immediately before the point of contact between the relevant fluid(s) and the anti-solvent. Instead or in addition, the supplied pressure of the target solution/suspension and/or of the second vehicle, to the particle formation vessel, may be maintained in excess of that of the anti-solvent fluid. It is also preferable to maintain the temperature of either or both of those two fluids, prior to their introduction into the particle formation vessel, in excess of that of the anti-solvent fluid.

The fluids are ideally introduced into the particle formation vessel with a smooth, continuous and preferably pulse-less or substantially pulse-less flow. This again helps prevent draw-back of fluids. Conventional apparatus may be used to ensure such fluid flows.

The densities of the fluids used will depend on the operating conditions; in the case where supercritical carbon dioxide is used as the anti-solvent fluid, its density might typically be between 0.1 and 0.9 g/ml.

The method of the invention preferably additionally involves collecting the particles following their formation, more preferably in the particle formation vessel itself. The method may also involve recovering the supercritical or near-critical solution formed on extraction of the vehicles into the anti-solvent fluid, separating the

WO 01/03821

PCT/GB00/02606

components of the solution and re-cycling one or more of those components for future use.

The method is preferably carried out in a substantially continuous, as opposed to batch-wise, manner.

5 The present invention will now be described, by way of example only, with reference to the accompanying illustrative drawings, in which:

Fig 1 illustrates schematically how a method in accordance with the present invention may be carried out;

10 Figs 2-4 are longitudinal cross sections through nozzles which may be used in carrying out the methods of the invention;

Fig 5 is an X-ray powder diffraction profile for the product of Example 2 below;

Figs 6 and 7 are X-ray powder diffraction profiles for pure salmeterol xinafoate and paracetamol respectively, for comparison with Fig 5;

15 Fig 8 is a high performance liquid chromatography (HPLC) chromatograph for the product of Example 2;

Fig 9 is an HPLC chromatograph for a paracetamol calibration standard, for comparison with Fig 8;

20 Figs 10 and 11 are scanning electron microscope (SEM) photographs of the products of Examples 1 and 2 respectively;

Figs 12 and 13 are SEM photographs of the products of Examples 3 and 4 respectively;

Figs 14 and 15 are UV absorption spectra for, respectively, pure paracetamol and the paracetamol-containing product of Example 4; and

25 Fig 16 shows the correlation between absorbance (268 nm) and concentration for standard paracetamol samples in DMF.

Detailed description

30 Referring firstly to Fig 1, the apparatus illustrated may be used to carry out a method in accordance with the present invention, as follows.

WO 01/03821

PCT/GB00/02606

A supercritical or near-critical anti-solvent fluid 1 (such as supercritical carbon dioxide) is introduced into a particle formation vessel 2 via a suitable fluid inlet such as nozzle 3. Co-introduced with the anti-solvent, also via nozzle 3, are a solution or suspension 4 of a target substance in a first vehicle, and a second vehicle 5. In the case shown, the anti-solvent passes through a cooler 6, pump 7, heat exchanger 8 and pulse dampener 9; the target solution/suspension passes through pump 10 and the second vehicle passes through pump 11.

The temperature and pressure inside the vessel 2 are controlled by means of the surrounding oven 12 and the back pressure regulator 13, to ensure that supercritical or near-critical conditions are maintained throughout particle formation. Thus, the solution formed when the anti-solvent extracts the two vehicles is also present as a single-phase supercritical/near-critical fluid.

The particles formed on contact between the anti-solvent and the other fluids are collected in the retaining device (such as a filter) 14, and the fluids are vented at 15.

Suitable nozzles for use in the Fig 1 apparatus are shown in Figs 2-4. In each case, the nozzle comprises two or more concentric, coaxial passages - two in the Fig 2 nozzle, three in the Fig 3 nozzle and four in the Fig 4 nozzle. Also in each case, at least one inner nozzle passage terminates slightly upstream (in use) of the outlet of one of its surrounding passages.

The Fig 2 nozzle, for instance, comprises an inner passage 20 and an outer passage 21 with respective internal diameters of 0.35 mm and 0.75 mm. A target solution/suspension may for instance be introduced through the inner passage and a mixture of an anti-solvent fluid and a second vehicle through the outer passage. The nozzle outlet diameter is 0.2 mm. Its central longitudinal axis is indicated by a dashed line.

The Fig 3 nozzle comprises inner, intermediate and outer passages 22, 23 and 24 respectively. Inner passage 22 terminates upstream of the outlet of the intermediate passage 23, allowing a degree of internal mixing to occur between fluids introduced through those two passages, immediately before they contact a third fluid (eg, an anti-

solvent fluid) introduced through the outer passage 24. The arrows indicate generally the directions of fluid flow through the in-use nozzle.

The Fig 4 nozzle comprises four coaxial passages, 25-28, again with staggered outlets. It may be used, for instance, to introduce a target solution/suspension through passage 26, and a second vehicle through the surrounding passage 27, "sandwiched" between inner and outer flows of an anti-solvent fluid in passages 25 and 28.

Experimental examples

10

Example 1

Using apparatus of the type illustrated in Fig 1, and a three-passage nozzle of the type shown in Fig 3, the method of the invention was used to co-precipitate two target substances, salmeterol xinafoate and paracetamol, to form an intimate mixture of the two pharmaceuticals.

The paracetamol was introduced in the form of a 1.5% w/v solution in a first vehicle (water), via the inner nozzle passage, with a flow rate of 0.04 ml/min. The salmeterol was introduced as a 0.5% w/v solution in a second vehicle, l-butanol, through the intermediate nozzle passage, at a flow rate of 1 ml/min. The molar ratio of the two vehicles, water:l-butanol, was 0.17:0.83. A supercritical carbon dioxide anti-solvent was introduced, with a flow rate of 18 ml/min (measured at the pump head), through the outer nozzle passage.

Water and l-butanol are immiscible, and of the two only l-butanol is soluble in supercritical carbon dioxide under the operating conditions used.

The particle formation vessel was a 50 ml Keystone vessel, maintained throughout the experiment at 150 bar and 50°C. Under these conditions carbon dioxide is more liquid-like than gas-like in properties.

The product was a fine, free flowing, white powder, which was collected in the vessel and subsequently stored free from light and moisture. Its SEM photograph, taken at 150x magnification, is shown in Fig 10.

WO 01/03821

PCT/GB00/02606

Example 2

Example 1 was repeated but with a 0.2% w/v salmeterol xinafoate solution rather than 0.5% w/v.

5 Again, the product was a fine, free flowing white powder, in which HPLC analysis confirmed the presence of paracetamol.

The X-ray powder diffraction profile for the product (Fig 5) differed slightly from those obtained for pure salmeterol (Fig 6) and pure paracetamol (Fig 7), indicating that an intimate mixture had been formed between the two co-precipitated
10 drugs.

HPLC analysis of the product (Fig 8) confirmed the presence of paracetamol in the powder mixture - a clear peak was produced at a similar retention time to that found for the paracetamol standard (Fig 9).

An SEM photograph of the product, taken at 150x magnification (Fig 11), shows
15 a considerable difference in crystal habit between the products of Examples 1 and 2. This change may be due to the lower salmeterol solution concentration and the resultant higher paracetamol concentration in the final product of Example 2.

Example 3

20 Again using apparatus of the type shown in Fig 1, and a three-passage coaxial nozzle, paracetamol was co-precipitated with L-poly lactic acid (L-PLA) using dichloromethane (DCM) and ethylene glycol (EG) as the two vehicles. DCM and EG are immiscible at room temperature and are not expected to be miscible or to have a critical solution temperature below 75°C (N. Godfrey, *Chemtech*, June 1972, pp 359-363), due
25 to the difference in their miscibility numbers. Both vehicles are soluble in supercritical carbon dioxide over a wide range of pressures and temperatures.

A 1.5% w/v solution of L-PLA (Resomer 206) in DCM was introduced into the apparatus at a rate of 0.4 ml/min via the inner nozzle passage. Through the intermediate passage, a 6% w/v solution of paracetamol in EG was introduced at 0.1 ml/min. The
30 molar ratio of EG:DCM was 0.274:0.736. Both solution streams were mixed and

dispersed with a supercritical carbon dioxide anti-solvent flowing through the outer nozzle passage at 30 ml/min (measured at the pump head). The particle formation vessel was a 50 ml high pressure vessel (Keystone) kept at 150 bar and 45°C. The nozzle outlet was 0.2 mm in diameter.

At the end of the experiment a fine, fluffy, easy-flowing white powder was collected and stored in a screw cap bottle for subsequent analysis. Fig 12 is a SEM photograph of the product at 4000x magnification.

Example 4

10 Example 3 was repeated at a higher operating temperature, 60°C. All other experimental conditions were unchanged.

A similar powder product was obtained; its SEM photograph is shown in Fig 13 (4000x magnification).

To verify the presence and quantity of paracetamol in the product, spectroscopic
15 absorption measurements were taken using an Ultrospec™ 4000 UV/Vis
spectrophotometer (Pharmacia Biotech). Pure paracetamol absorbs UV light at 268 nm
(see the UV absorption spectrum shown in Fig 14). This is a region of the spectrum in
which L-PLA does not absorb.

A 0.01 mg/ml DMF solution of the product was tested. This was expected to contain 50% w/w of paracetamol, in view of the quantities of drug and polymer introduced into the particle formation vessel, assuming no solute loss into the carbon dioxide anti-solvent. Its absorbance was found to be 0.213 (absorption spectrum shown in Fig 15).

Fig 16 shows the correlation between absorbance (268 nm) and concentration for standard paracetamol samples in DMF. Substitution of an absorbance value (y) of 0.213 into the equation shown on the graph gives a concentration (x) of 0.0053 mg/ml (dashed line in Fig 16). This is very close to the theoretical value of 0.0050, indicating that the paracetamol introduced into the particle formation system has been almost fully retained and that neither the L-PLA nor the paracetamol is soluble in supercritical carbon dioxide under the working conditions used.

WO 01/03821

PCT/GB00/02606

AMENDED CLAIMS

[received by the International Bureau on 14 November 2000 (14.11.00);
original claims 2-35 replaced by new claims 2-36; remaining claim unchanged (5 pages)]

- 1 A method for forming particles of a target substance, the method comprising
(a) co-introducing into a particle formation vessel, the temperature and
5 pressure in which are controlled, an anti-solvent fluid which is either a
supercritical or a near-critical fluid; a solution or suspension of the target
substance in a first vehicle (the "target solution/suspension"); and a second
vehicle which is soluble or substantially soluble in the anti-solvent fluid; and
(b) using the anti-solvent fluid to disperse the target solution/suspension and
10 the second vehicle, and to extract the vehicles, substantially simultaneously
and substantially immediately on introduction of the fluids into the particle
formation vessel, wherein the second vehicle is immiscible with the first
vehicle, and wherein contact between the target solution/suspension and the
second vehicle occurs a sufficiently short period of time before their
15 dispersion by the anti-solvent fluid, and with sufficient physical mixing, as to
allow only insignificant, if any, phase separation to occur between the two
vehicles between their contact with one another and their dispersion.
- 2 A method according to claim 1, provided that the second vehicle is not a
supercritical fluid.
- 20 3 A method according to claim 1 or claim 2, wherein contact between the target
solution/suspension and the second vehicle occurs within a fluid inlet means
used to introduce the fluids into the particle formation vessel, or at or
immediately before the point of entry of the vehicles into the inlet means.
- 4 A method according to claim 3, wherein the contact occurs within the fluid
25 inlet means.
- 5 A method according to claim 3 or claim 4, wherein the second vehicle is
introduced into the inlet means separately from the target solution/suspension
and the anti-solvent fluid, its direction of flow into the particle formation
vessel being concurrent, and coaxial or substantially coaxial, with that of the
30 target solution/suspension.

WO 01/03821

PCT/GB00/02606

- 6 A method according to any one of claims 3 to 5, wherein the contact between the target solution/suspension and the second vehicle occurs either substantially simultaneously with, or immediately before, dispersion of the two vehicles by the anti-solvent fluid.
- 5 7 A method according to claim 6, wherein the contact occurs within about 0.001-10 seconds of the dispersion of the target solution/suspension and the second vehicle by the anti-solvent fluid.
- 8 A method according to claim 7, wherein the contact occurs within about 0.01-5 seconds of the dispersion.
- 10 9 A method according to any one of the preceding claims, wherein the first and second vehicles are immiscible in all or substantially all proportions.
- 10 A method according to claim 9, wherein the two vehicles are immiscible at first:second vehicle molar ratios lower than 20:80.
- 11 A method according to any one of the preceding claims, wherein the first vehicle is water and the second vehicle is a C₄ or higher alcohol.
- 15 12 A method according to any one of claims 1 to 10, wherein the first vehicle is methanol and the second vehicle is a C₅ or higher alkane.
- 13 A method according to any one of claims 1 to 10, wherein the first vehicle is ethylene glycol and the second vehicle is a haloalkane.
- 20 14 A method according to any one of the preceding claims, wherein the first and second vehicles are selected from the group consisting of water and 1-butanol; water and ethyl acetate; methanol and n-pentane; methanol and n-octane; methanol and hexane; methanol and cyclohexane; DMF (dimethyl formamide) and a higher alkane; DMSO (dimethyl sulphoxide) and a higher alkane; ethyl ether and DMSO; ethylene glycol and dichloromethane; ethylene glycol and 1,2-dichloroethane; glycerol and 3-pentanone; glycerol and ethyl acetate; 2-methoxyethanol and tetradecane; ethylformamide and hexane; 1-amino-2-propanol and isopropyl ether; 2-aminoethanol and dichloromethane; 2-
- 25

WO 01/03821

PCT/GB00/02606

aminoethanol and ethyl ether; 1,4-butanediol and butyl acetate; and water and dichloromethane.

- 15 A method according to any one of the preceding claims, wherein the relative
amounts of the first and second vehicles used are such that, under the
5 operating conditions used, the target solution/suspension and the second
vehicle form a single phase mixture at the time of their contact with the anti-
solvent fluid.
- 16 A method according to any one of the preceding claims, wherein there is an
excess of the second vehicle over the first, at their point of contact with the
10 anti-solvent fluid.
- 17 A method according to claim 16, wherein the molar ratio of the first to the
second vehicle is less than 1:6.
- 18 A method according to any one of the preceding claims, wherein the target
substance is for use in or as a pharmaceutical or pharmaceutical excipient.
- 15 19 A method according to any one of the preceding claims, wherein the target
substance is a hydrophilic material.
- 20 A method according to claim 19, wherein the target substance is a sugar,
protein or enzyme.
- 21 A method according to any one of the preceding claims, wherein two or more
20 target substances are co-precipitated from the first and/or the second vehicle.
- 22 A method according to any one of the preceding claims, wherein the anti-
solvent fluid is a supercritical fluid.
- 23 A method according to any one of the preceding claims, wherein each of the
two vehicles comprises a single fluid material.
- 25 24 A method according to any one of the preceding claims, wherein the second
vehicle is an anti-solvent for the target substance, and contains a crystallisation
seed of a material which is insoluble in the second vehicle, to induce

ART 34 AMDT

WO 01/03821

PCT/GB00/02606

nucleation of the target substance when the second vehicle comes into contact with the target solution/suspension.

- 25 A method according to claim 24, wherein the crystallisation seed is a pharmaceutically acceptable carrier and the target substance is for use in or as a pharmaceutical.
- 26 A method according to claim 24, wherein the crystallisation seed comprises a pharmaceutically active material and the target substance comprises a material to be coated onto the pharmaceutically active material.
- 27 A method according to any one of the preceding claims, wherein the flow rate of the anti-solvent fluid is higher than those of the other fluids.
- 28 A method according to claim 27, wherein the ratio of the target solution/suspension flow rate to the anti-solvent flow rate, both measured at or immediately prior to the two fluids coming into contact with one another, is between 0.01 and 0.2.
- 29 A method according to any one of the preceding claims, wherein at the point of extraction of the two vehicles, into the anti-solvent fluid, they together constitute between 1 and 20 mole % of the fluid mixture then formed.
- 30 A method according to any one of the preceding claims, wherein the fluids are co-introduced into the particle formation vessel in a manner such that:
- (a) the anti-solvent fluid and the target solution/suspension both enter the vessel at the same or substantially the same point, which is the same or substantially the same as the point at which they meet; and
 - (b) the fluid inlet used to co-introduce the fluids is arranged so that the mechanical energy of the anti-solvent flow can facilitate intimate mixing of the fluids and also disperse them, and so that the anti-solvent can simultaneously extract the vehicles, at the point where the fluids meet.

WO 01/03821

PCT/GB00/02606

- 31 A method according to claim 30, wherein the anti-solvent fluid and the target solution/suspension are co-introduced into the particle formation vessel with concurrent, and coaxial or substantially coaxial, directions of flow.
- 5 32 A method according to claim 30 or claim 31, wherein the fluid inlet comprises a nozzle having an outlet end communicating with the interior of the particle formation vessel, and two or more coaxial passages which terminate adjacent or substantially adjacent one another at the outlet end.
- 33 A method according to claim 32, wherein the nozzle has three coaxial passages, an inner, an intermediate and an outer.
- 10 34 A method according to claim 32 or claim 33, wherein the outlet of an inner nozzle passage is located slightly upstream, in use, of that of a surrounding passage, to allow a degree of internal mixing between fluids introduced through the two passages.
- 15 35 A method according to any one of the preceding claims, which additionally involves controlling one or more of (i) the flow rates of the anti-solvent fluid and/or the target solution/suspension and/or the second vehicle, (ii) the relative amounts of the two vehicles, (iii) the concentration of the target substance in the first vehicle, and (iv) the temperature and pressure inside the particle formation vessel, so as to influence the physicochemical characteristics of the particles formed.
- 20 36 A method for forming particles of a target substance, which is substantially as herein described with reference to the accompanying illustrative drawings.

~~33~~ 28


(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number
WO 01/03821 A1

- (51) International Patent Classification⁷: B01J 2/04, B05D 1/02, A61K 9/16
- (21) International Application Number: PCT/GB00/02606
- (22) International Filing Date: 7 July 2000 (07.07.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 9915975.8 7 July 1999 (07.07.1999) GB
- (71) Applicant (for all designated States except US): **BRADFORD PARTICLE DESIGN PLC** [GB/GB]; Unit 69 Listerhills Science Park, Campus Road, Bradford BD7 1HR (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **HANNA, Mazen, Hermiz** [GB/GB]; 6 Woodland Grove, Heaton BD9 6PQ (GB). **YORK, Peter** [GB/GB]; 47 Parish Ghyll Drive, Ilkley LS29 9PR (GB).
- (54) Title: METHOD OF PARTICLE FORMATION
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- With international search report.
 - With amended claims.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(57) Abstract: The invention provides a method for forming particles of a target substance, comprising (a) co-introducing into a particle formation vessel, under controlled temperature and pressure, a supercritical or near-critical anti-solvent fluid; a "target solution or suspension" of the target in a first vehicle; and a second vehicle which is soluble in the anti-solvent fluid; and (b) using the anti-solvent to disperse the target solution/suspension and the second vehicle, and to extract the vehicles, substantially simultaneously and substantially immediately on introduction of the fluids into the particle formation vessel, wherein the second vehicle is immiscible with the first, and wherein contact between the target solution/suspension and the second vehicle occurs a sufficiently short period of time before their dispersion by the anti-solvent, and with sufficient physical mixing, as to allow only insignificant, if any, phase separation to occur between the two vehicles between their contact with one another and their dispersion.


WO 01/03821 A1

WO 01/03821

PCT/GB00/02606

1/10

Fig.1.



WO 01/03821

PCT/GB00/02606

2/10

Fig.2.




Fig.3.





Fig.4.



SUBSTITUTE SHEET (RULE 26)

WO 01/03821

PCT/GB00/02606

3/10





Fig.5.

WO 01/03821

PCT/GB00/02606


4/10



WO 01/03821

PCT/GB00/02606

5/10



WO 01/03821

PCT/GB00/02606

6/10

Fig.8.





Fig.9.



WO 01/03821

PCT/GB00/02606

7/10

Fig.10.



Fig.11.



WO 01/03821

PCT/GB00/02606

8/10

Fig.12.




Fig.13.



WO 01/03821

PCT/GB00/02606

9/10

Fig.14.






Fig.15.



WO 01/03821

PCT/GB00/02606

10/10



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR
DESIGN
PATENT APPLICATION
(37 CFR 1.63)**

☐ Declaration Submitted with Initial Filing OR ☒ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number	0112.00
First Named Inventor	Hanna, Mazen H.
COMPLETE IF KNOWN	
Application Number	10 / 030,392 ✓
Filing Date	1/7/2002 ✓
Art Unit	
Examiner Name	

As the below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original and first inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Method of Particle Formation

(Title of the Invention)

the specification of which

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) 1/7/2002 ✓ as United States Application Number or PCT International

Application Number 10/030,392 ✓ and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
PCT/GB00/02606	WO	7/7/2000	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
9915975	GB	7/8/1999	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9915975.8		7-7-99	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent ApplicationDirect all correspondence to: ☒ Customer Number or Bar Code Label 21968 OR ☐ Correspondence address below

Name

Address

City

State

ZIP

Country

Telephone

Fax

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR: ☐ A petition has been filed for this unsigned inventorGiven Name
(first and middle [if any]) Mazen H.Family Name
or Surname HannaInventor's
Signature *Mazen Hanna*Date 23/4/02Residence: City Bradford GBX

State

Country UKUnited
Citizenship KingdomMailing Address 6 Woodland GroveCity Bradford

State

ZIP BD9 6PQUnited
Country KingdomNAME OF SECOND INVENTOR: ☐ A petition has been filed for this unsigned inventorGiven Name
(first and middle [if any]) PeterFamily Name
or Surname YorkInventor's
Signature *Peter York*Date 25.4.02Residence: City Ilkley GBX

State

Country UKUnited
Citizenship KingdomMailing Address 47 Parish Ghyll DriveCity Ilkley

State

ZIP LS29 9PRUnited
Country Kingdom☐ Additional inventors are being named on the 0 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.